ABBV vs NKE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and NIKE, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-17.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
NIKE, Inc. · Consumer Cyclical
$35.78
+9.9% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
NKE has more upside to fair value
(+9.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
NKE |
| Current Price |
$261.70 |
$35.78 |
| Fair Value Estimate |
$259.04 |
$39.33 |
| Upside to Fair Value |
-1.0%
|
+9.9%
|
| Market Cap |
$462.4B |
$53.0B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
12.0x
|
| Price / Sales |
7.2x
|
1.1x
|
| Price / FCF |
23.6x
|
24.3x
|
| Revenue Growth YoY |
+10.2%
|
-1.1%
|
| Gross Margin |
71.5%
|
42.9%
|
| Operating Margin |
29.3%
|
8.2%
|
| Return on Equity |
-136.5%
|
22.0%
|
| Dividend Yield |
2.61% |
4.58% |
| FCF Yield |
4.25%
|
4.12%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
NIKE designs, markets and distributes athletic footwear, apparel and equipment through the Nike, Jordan and Converse brands, supported by global athlete marketing, valuable intellectual property and a broad wholesale and owned-digital network. Business quality is medium: its brand moat and 22.0% ROE remain meaningful, but the moat is narrowing amid intense competition, weak direct sales and uneve…
Accumulation Zones
| Metric |
ABBV |
NKE |
| Zone Low |
$194.28 |
$29.50 |
| Zone High |
$220.18 |
$33.43 |
| In Buy Zone? |
No
|
No
|